Drug Coverage
Drug Coverage
Navigating Drug Formularies
Schaeffer experts evaluate trends in drug formularies and utilization restrictions to determine whether patients are getting access to high-value medicines.
Related Topics
Top Drug Coverage Stories View All
Perspective
When Cost-Effectiveness Thresholds Drift: Global HTA, MFN Pricing, and the Need for a Coherent Framework
Featured Experts: William Padula
In The News View All
Pink Sheet
Chen warns MFN could have unintended consequences and highlights need for US value-based pricing
Featured Experts: Alice Chen
MinnPost
Mulligan explains how 340B program encourages hospitals to favor more expensive drugs
Featured Experts: Karen Mulligan
Bloomberg
Lakdawalla explains why MFN could hold back new treatments in Europe
Featured Experts: Darius Lakdawalla
Financial Times
Medicare’s plan to speed up coverage of new medical devices may expand access to innovation, Padula says
Featured Experts: William Padula
The Washington Post
Padula outlines possible factors driving a recent decline in prescription drug costs
Featured Experts: William Padula
Featured Perspective
A Missed Chance to Make America Healthier and Richer
Medicare should revisit its decision not to broadly cover anti-obesity medications, considering the enormous value expanded access would generate for society.
Experts: Alison Sexton Ward, Dana Goldman
Drug Coverage
Experts
Featured Research
Medicare Part D Plans Increased Restrictions on Drug Coverage
Medicare Part D plans excluded more compounds from coverage or subjected more of them to review before patients can access treatments, USC researchers found.
Experts: Geoffrey Joyce, Karen Van Nuys
